For a stock that had been struggling for significance for much of the past year, this dramatic shift was not merely a rally — ...

The Portfolio returned 7.33% gross, significantly outperforming the MSCI World Health Care Index's 3.12% return. Click here ...

Through the first three quarters of 2025, M&A activity overtook the entire 2024 total, according to Endpoints News. Editor and founder John Carroll wrote in October this might be the best time in 15 ...

Wave's bullish start to the week was driven by the encouraging readout of a Phase 1 clinical study of WVE-007, its obesity ...

Actively moving up the value chain toward drug discovery, development and digital therapeutics is key to sustaining the State ...

Salesforce (NYSE: CRM), the world’s #1 AI CRM, announced today that Novartis (NYSE: NVS), a leading global innovative ...

Wave Life Sciences Ltd is a pioneering force in genetic medicine, focusing on creating innovative treatments for serious ...

Humans have it. So does Drosophila. But not yeast. That "it" is a small pause at the start of gene activity—a brief molecular halt that may have helped life evolve from simple cells to complex animals ...

The Board on Life Sciences (BLS) was established in 1984 to serve as the focal point for addressing critical, emerging policy and technical issues associated with the life sciences and biotechnology ...

Life Sciences ventures face high levels of scientific, clinical and commercial pathway uncertainty, and these uncertainties present many opportunities for entrepreneurial innovation. This course is ...

The 2024-25 Sustainability Report reflects the company’s long-term view-one that places science, responsibility, and ...

Then, life science companies were scrambling for space — industrial vacancy rates dipped to as low as 2%. Deep‑pocketed developers from Silicon Valley and Boston came and spent millions speculating on ...